Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer
Yes === Purpose: Despite positive responses in phase II clinical trials, the bioreductive prodrug apaziquone failed to achieve statistically significant activity in non-muscle invasive bladder cancer in phase III trials. Apaziquone was administered shortly after transurethral resection and here we...
| Main Authors: | , , |
|---|---|
| Language: | en |
| Published: |
2019
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10454/17119 |